Scarica l'app Stockscreener
226.75
0.36%
0.535
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$226.22
Aprire:
$226.22
Volume 24 ore:
1.42M
Relative Volume:
0.26
Capitalizzazione di mercato:
$400.94B
Reddito:
$58.33B
Utile/perdita netta:
$3.73B
Rapporto P/E:
107.91
EPS:
2.1013
Flusso di cassa netto:
$18.24B
1 W Prestazione:
-1.59%
1M Prestazione:
+4.98%
6M Prestazione:
+32.24%
1 anno Prestazione:
+19.20%
Intervallo 1D:
$225.46
$227.25
Intervallo di 1 settimana:
$225.32
$234.68
Portata 52W:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
226.96 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
821.32 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.86 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
NVS
Novartis Ag Adr
|
130.74 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.18 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AbbVie's Bretisilocin Hit With Enveric IP Claim - Yahoo
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 - GlobeNewswire Inc.
Can AbbVie Inc. stock outperform in 2025 bull marketFed Meeting & Daily Oversold Bounce Ideas - newser.com
Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie - GuruFocus
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisiloc - PharmiWeb.com
AbbVie breaks ground on new API manufacturing plant in North Chicago - Chicago Construction News
AbbVie could face patent battle over depression asset gained in Gilgamesh deal - Seeking Alpha
Enveric contests patent review petition related to AbbVie acquisition - Investing.com
AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Breti - GuruFocus
Top Medical Aesthetics Companies in 2025 - vocal.media
AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump - Yahoo Finance
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie? - The Globe and Mail
Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades' - Benzinga
Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally? - Yahoo Finance
Abbvie gets USFDA approval for updated indication statement for Rinvoq for Inflammatory Bowel Disease - Medical Dialogues
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Cr - GuruFocus
FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colit - GuruFocus
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug - Stocktwits
FDA approves updated indication for AbbVie’s RINVOQ in IBD treatment - Investing.com
Use after 1 approved systemic therapy — AbbVie gets FDA approval to update RINVOQ IBD label allowing pre‑TNF use - Stock Titan
2 Dividend Stocks to Double Up on Right Now - The Globe and Mail
Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - MarketScreener
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - Investing News Network
AbbVie (ABBV) to Present New Antibody-Drug Conjugate Data at ESM - GuruFocus
Atria Wealth Solutions Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Envestnet Portfolio Solutions Inc. - MarketBeat
Concord Asset Management LLC VA Purchases 1,691 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Vest Financial LLC - MarketBeat
Griffin Asset Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
M.E. Allison & CO. Inc. Has $466,000 Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by MOKAN Wealth Management Inc. - MarketBeat
AbbVie Inc. $ABBV is Welch Group LLC's 9th Largest Position - MarketBeat
Almanack Investment Partners LLC. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Criteria Caixa S.A.U. Sells 47,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Cwm LLC Has $60.03 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
Vanguard Personalized Indexing Management LLC Acquires 37,680 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by OFI Invest Asset Management - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Buys Shares of 23,920 AbbVie Inc. $ABBV - MarketBeat
Sather Financial Group Inc Purchases New Position in AbbVie Inc. $ABBV - MarketBeat
2,500 Shares in AbbVie Inc. $ABBV Bought by Summa Corp. - MarketBeat
Johnson Investment Counsel Inc. Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades - Yahoo Finance
AbbVie Inc. $ABBV Holdings Lowered by Natural Investments LLC - MarketBeat
Fifth Third Wealth Advisors LLC Sells 4,542 Shares of AbbVie Inc. $ABBV - MarketBeat
One Degree Advisors Inc Buys New Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Conning Inc. - MarketBeat
Drucker Wealth 3.0 LLC Purchases 2,817 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Eastern Bank - MarketBeat
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):